Development and validation of the PERCEPT-PREVENT tool to determine risk perception and attitudes towards digestive cancer screening.
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
01 Jan 2024
01 Jan 2024
Historique:
medline:
7
12
2023
pubmed:
23
11
2023
entrez:
23
11
2023
Statut:
ppublish
Résumé
Colorectal cancer (CRC) screening is recommended worldwide, while gastric cancer (GC) screening may also be defendable in some settings. However, adherence rates and factors influencing participation are not well characterized. This study aimed to validate a tool to determine risk perception of CRC and GC and also of endoscopy-related complications. A questionnaire in CRC risk perception based on the Health Belief Model was used. Forward/backward translation (English-Portuguese) and cultural adaptation were performed. After revision by a panel of experts, the questionnaire was adapted to target GC risk perception and perceptions towards endoscopy-related complications. The final version of the questionnaire (PERCEPT-PREVENT tool) was applied to 44 individuals, through telephonic interview, at enrolment and at intervals ≤3 weeks. Test-retest reliability and agreement were assessed. Almost perfect reliability between test and retest was obtained for CRC symptom knowledge score (ICC = 0.88), risk factor knowledge score (ICC = 0.89), and perceived severity (ICC = 0.84). At least moderate agreement between test and retest was obtained for GC symptom knowledge score (ICC = 0.94), risk factor knowledge score (ICC = 0.92), and perceived severity (ICC = 0.58). Test-retest reliability was assessed for barrier domains [faecal occult blood test ICC = 0.63; colonoscopy ICC = 0.79; upper GI endoscopy (UGIE) ICC = 0.83]. A total of 91% and 98% of participants gave the same answer in the test and retest for preferred method of CRC screening and intention to undergo UGIE for GC screening combined with a screening colonoscopy, respectively. PERCEPT-PREVENT is a valid and reliable tool for CRC and GC risk perception evaluation.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Colorectal cancer (CRC) screening is recommended worldwide, while gastric cancer (GC) screening may also be defendable in some settings. However, adherence rates and factors influencing participation are not well characterized. This study aimed to validate a tool to determine risk perception of CRC and GC and also of endoscopy-related complications.
METHODS
METHODS
A questionnaire in CRC risk perception based on the Health Belief Model was used. Forward/backward translation (English-Portuguese) and cultural adaptation were performed. After revision by a panel of experts, the questionnaire was adapted to target GC risk perception and perceptions towards endoscopy-related complications. The final version of the questionnaire (PERCEPT-PREVENT tool) was applied to 44 individuals, through telephonic interview, at enrolment and at intervals ≤3 weeks. Test-retest reliability and agreement were assessed.
RESULTS
RESULTS
Almost perfect reliability between test and retest was obtained for CRC symptom knowledge score (ICC = 0.88), risk factor knowledge score (ICC = 0.89), and perceived severity (ICC = 0.84). At least moderate agreement between test and retest was obtained for GC symptom knowledge score (ICC = 0.94), risk factor knowledge score (ICC = 0.92), and perceived severity (ICC = 0.58). Test-retest reliability was assessed for barrier domains [faecal occult blood test ICC = 0.63; colonoscopy ICC = 0.79; upper GI endoscopy (UGIE) ICC = 0.83]. A total of 91% and 98% of participants gave the same answer in the test and retest for preferred method of CRC screening and intention to undergo UGIE for GC screening combined with a screening colonoscopy, respectively.
DISCUSSION
CONCLUSIONS
PERCEPT-PREVENT is a valid and reliable tool for CRC and GC risk perception evaluation.
Identifiants
pubmed: 37994621
doi: 10.1097/MEG.0000000000002671
pii: 00042737-990000000-00264
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
45-51Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Sung H, Siegel RL, Rosenberg PS, Jemal A. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. Lancet Public Health 2019; 4:e137–e147.
Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut 2023; 72:338–344.
Araghi M, Soerjomataram I, Bardot A, Ferlay J, Cabasag CJ, Morrison DS, et al. Changes in colorectal cancer incidence in seven high-income countries: a population-based study. Lancet Gastroenterol Hepatol 2019; 4:511–518.
Cardoso R, Guo F, Heisser T, Hackl M, Ihle P, De Schutter H, et al. Colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study. Lancet Oncol 2021; 22:1002–1013.
Cardoso R, Guo F, Heisser T, De Schutter H, Van Damme N, Nilbert MC, et al. Proportion and stage distribution of screen-detected and non-screen-detected colorectal cancer in nine European countries: an international, population-based study. Lancet Gastroenterol Hepatol 2022; 7:711–723.
Moutel G, Duchange N, Lievre A, Orgerie MB, Jullian O, Sancho-Garnier H, et al. Low participation in organized colorectal cancer screening in France: underlying ethical issues. Eur J Cancer Prev 2019; 28:27–32.
Cardoso R, Guo F, Heisser T, Hoffmeister M, Brenner H. Utilisation of colorectal cancer screening tests in European Countries by type of screening offer: results from the European Health Interview Survey. Cancers (Basel) 2020; 12:1409–1409.
Guo F, Chen C, Schottker B, Holleczek B, Hoffmeister M, Brenner H. Changes in colorectal cancer screening use after introduction of alternative screening offer in Germany: prospective cohort study. Int J Cancer 2020; 146:2423–2432.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68:394–424.
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49:1374–1403.
Areia M, Spaander MC, Kuipers EJ, Dinis-Ribeiro M. Endoscopic screening for gastric cancer: a cost-utility analysis for countries with an intermediate gastric cancer risk. United European Gastroenterol J 2018; 6:192–202.
Saftoiu A, Hassan C, Areia M, Bhutani MS, Bisschops R, Bories E, et al. Role of gastrointestinal endoscopy in the screening of digestive tract cancers in Europe: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement. Endoscopy 2020; 52:293–304.
Faria L, Silva JC, Rodriguez-Carrasco M, Pimentel-Nunes P, Dinis-Ribeiro M, Libanio D. Gastric cancer screening: a systematic review and meta-analysis. Scand J Gastroenterol 2022; 57:1178–1188.
Koo JH, Leong RW, Ching J, Yeoh K-G, Wu D-C, Murdani A, et al.; Asia Pacific Working Group in Colorectal Cancer. Knowledge of, attitudes toward, and barriers to participation of colorectal cancer screening tests in the Asia-Pacific region: a multicenter study. Gastrointest Endosc 2012; 76:126–135.
Sung JJ, Choi SY, Chan FK, Ching JY, Lau JT, Griffiths S. Obstacles to colorectal cancer screening in Chinese: a study based on the health belief model. Am J Gastroenterol 2008; 103:974–981.
Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine (Phila Pa 1976) 2000; 25:3186–3191.
Epstein J, Santo RM, Guillemin F. A review of guidelines for cross-cultural adaptation of questionnaires could not bring out a consensus. J Clin Epidemiol 2015; 68:435–441.
Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, et al.; ISPOR Task Force for Translation and Cultural Adaptation. Principles of good practice for the translation and cultural adaptation process for patient-reported outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. Value Health 2005; 8:94–104.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33:159–74.
Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307–310.
McHugh ML. Interrater reliability: the kappa statistic. Biochem Med 2012; 22:276–282.
Almadi MA, Mosli MH, Bohlega MS, Al Essa MA, AlDohan MS, Alabdallatif TA, et al. Effect of public knowledge, attitudes, and behavior on willingness to undergo colorectal cancer screening using the health belief model. Saudi J Gastroenterol 2015; 21:71–77.
Almadi MA, Alghamdi F. The gap between knowledge and undergoing colorectal cancer screening using the Health Belief Model: a national survey. Saudi J Gastroenterol 2019; 25:27–39.
Torosian T, Abrami EA, Massoumi RL, Harutyunyan NM, Dallakyan G, Hovhannisyan H, et al. Assessing knowledge and perceptions of colorectal cancer screening in Armenia. J Surg Res 2021; 257:616–624.
Wong FMF. Factors associated with knowledge, attitudes, and practice towards colorectal cancer and its screening among people aged 50-75 years. Int J Environ Res Public Health 2021; 18:4100.
Kwak MS, Choi KS, Park S, Park EC. Perceived risk for gastric cancer among the general Korean population: a population-based survey. Psychooncology 2009; 18:708–715.
Hatamian S, Etesam S, Mazidimoradi A, Momenimovahed Z, Salehiniya H. The barriers and facilitators of gastric cancer screening: a systematic review. J Gastrointest Cancer 2021; 52:839–845.